Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by apply...
Saved in:
Published in | The European respiratory journal Vol. 59; no. 2; p. 2003979 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
European Respiratory Society
01.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF.
To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside
to the encoded gene (
-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal.
MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10
and OR 0.76, 95% CI 0.68-0.86; p=1.1×10
, respectively). Sensitivity analyses including multiple
-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10
and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10
and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of
for IPF.
An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF. |
---|---|
AbstractList | After undertaking an efficient scan of 834 circulating proteins for their role in IPF risk using Mendelian randomisation, we found that individuals with
genetically increased circulating FUT3 levels had lower risk of developing IPF
https://bit.ly/3zCX8zf Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF.BACKGROUNDIdiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF.To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal.METHODSTo identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal.MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10-7 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10-5, respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10-6 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10-4 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF.RESULTSMR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10-7 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10-5, respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10-6 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10-4 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF.An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF.CONCLUSIONSAn efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside to the encoded gene ( -single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal. MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10 , respectively). Sensitivity analyses including multiple -SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of for IPF. An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF. |
Author | Schwartz, David A. Richards, J. Brent Jenkins, R. Gisli Koido, Masaru Zhou, Sirui Wain, Louise V. Nakanishi, Tomoko Forgetta, Vincenzo Lathrop, G. Mark Cerani, Agustin Leavy, Olivia C. Wolters, Paul J. Assayag, Deborah Yang, Ivana V. Allen, Richard J. |
AuthorAffiliation | 2 Centre for Clinical Epidemiology, Dept of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada 15 McGill Genome Centre and Dept of Human Genetics, McGill University, Montréal, QC, Canada 6 Dept of Health Sciences, University of Leicester, Leicester, UK 16 Dept of Medicine, School of Medicine, University of California, San Francisco, CA, USA 17 Dept of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA 1 Dept of Human Genetics, McGill University, Montréal, QC, Canada 10 National Heart and Lung Institute, Imperial College London, London, UK 7 Dept of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan 19 Dept of Twin Research, King's College London, London, UK 9 Translational Research in Respiratory Diseases, Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, QC, Canada 13 Center for Genes, Environment and Health and Dept of Medicine, National Jewish Health, Denver, |
AuthorAffiliation_xml | – name: 14 Dept of Medicine, School of Medicine, University of Colorado Denver, Aurora, CO, USA – name: 3 Kyoto–McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan – name: 5 Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC, Canada – name: 7 Dept of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan – name: 10 National Heart and Lung Institute, Imperial College London, London, UK – name: 11 Dept of Interstitial Lung Disease, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK – name: 19 Dept of Twin Research, King's College London, London, UK – name: 8 Dept of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada – name: 1 Dept of Human Genetics, McGill University, Montréal, QC, Canada – name: 12 National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK – name: 17 Dept of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA – name: 4 Japan Society for the Promotion of Science, Tokyo, Japan – name: 16 Dept of Medicine, School of Medicine, University of California, San Francisco, CA, USA – name: 6 Dept of Health Sciences, University of Leicester, Leicester, UK – name: 18 Division of Endocrinology, Dept of Medicine, Jewish General Hospital, McGill University, Montréal, QC, Canada – name: 9 Translational Research in Respiratory Diseases, Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, QC, Canada – name: 13 Center for Genes, Environment and Health and Dept of Medicine, National Jewish Health, Denver, CO, USA – name: 15 McGill Genome Centre and Dept of Human Genetics, McGill University, Montréal, QC, Canada – name: 2 Centre for Clinical Epidemiology, Dept of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada |
Author_xml | – sequence: 1 givenname: Tomoko orcidid: 0000-0001-9510-5646 surname: Nakanishi fullname: Nakanishi, Tomoko – sequence: 2 givenname: Agustin orcidid: 0000-0002-9633-7796 surname: Cerani fullname: Cerani, Agustin – sequence: 3 givenname: Vincenzo orcidid: 0000-0002-6061-4720 surname: Forgetta fullname: Forgetta, Vincenzo – sequence: 4 givenname: Sirui orcidid: 0000-0003-4963-0815 surname: Zhou fullname: Zhou, Sirui – sequence: 5 givenname: Richard J. orcidid: 0000-0002-8450-3056 surname: Allen fullname: Allen, Richard J. – sequence: 6 givenname: Olivia C. orcidid: 0000-0002-1503-5535 surname: Leavy fullname: Leavy, Olivia C. – sequence: 7 givenname: Masaru orcidid: 0000-0002-0348-0666 surname: Koido fullname: Koido, Masaru – sequence: 8 givenname: Deborah orcidid: 0000-0002-2497-9984 surname: Assayag fullname: Assayag, Deborah – sequence: 9 givenname: R. Gisli orcidid: 0000-0002-7929-2119 surname: Jenkins fullname: Jenkins, R. Gisli – sequence: 10 givenname: Louise V. orcidid: 0000-0003-4951-1867 surname: Wain fullname: Wain, Louise V. – sequence: 11 givenname: Ivana V. orcidid: 0000-0002-1018-489X surname: Yang fullname: Yang, Ivana V. – sequence: 12 givenname: G. Mark orcidid: 0000-0002-2660-7105 surname: Lathrop fullname: Lathrop, G. Mark – sequence: 13 givenname: Paul J. orcidid: 0000-0002-3108-6164 surname: Wolters fullname: Wolters, Paul J. – sequence: 14 givenname: David A. orcidid: 0000-0001-6743-8443 surname: Schwartz fullname: Schwartz, David A. – sequence: 15 givenname: J. Brent orcidid: 0000-0002-3746-9086 surname: Richards fullname: Richards, J. Brent |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34172473$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UU1vFCEYJk2N3W79BU0MRy9T-ZoZ8GBiGltNanppz-RdYFqUhRWYJnvvD5dtu0Y9eAHy8nzA8xyjw5iiQ-iUkjNKJX9PuVKcEH5GuBpVxwgjB2ixm3a78SFaEEV4RxUfjtBxKd8JoYPg9DU64oKOTIx8gR4vXXTVGwhhi3002UFxFhufzRyg-niHL25vOA7uwYW2gi24JpydnU3DZV9-4DRhb33aQL33Bm_msE4R8hZPfpVT8eUDBvzNReuCh4gzRJvWvjTxFHGps92eoFcThOLevOxLdHvx-eb8S3d1ffn1_NNVZwTpawdyYnayo4UVlWDYKKx0ExPtAEQYYod-NU5WjsPApOJ2UIxwwaUUwwQEgC_Rx2fdzbxaO2tcrBmC3mS_bu_VCbz--yb6e32XHrSUTVD1TeDdi0BOP2dXqm4fMS4EiC7NRbNe9L0aafNdord_ev022UffAOoZYFpIJbtJG1-fQmnWPmhK9K5mva9ZP9WsdzU3Lv-Hu5f_H-sX19ytAg |
CitedBy_id | crossref_primary_10_1136_thorax_2024_221398 crossref_primary_10_1093_postmj_qgae140 crossref_primary_10_1186_s12890_024_03289_y crossref_primary_10_3390_jcm12113713 crossref_primary_10_1016_j_ocarto_2024_100540 crossref_primary_10_1371_journal_pone_0300423 crossref_primary_10_1111_resp_14511 crossref_primary_10_1111_cts_13442 crossref_primary_10_1164_rccm_202401_0238SO crossref_primary_10_3389_fimmu_2023_1168023 crossref_primary_10_1007_s00432_023_04612_6 crossref_primary_10_1038_s41598_025_85338_y |
Cites_doi | 10.1002/ijc.32033 10.1136/bmj.k601 10.1093/bioinformatics/btz469 10.1093/oxfordjournals.molbev.a004138 10.1002/pmic.201900278 10.1056/NEJMoa1402584 10.1371/journal.pmed.0050093 10.1016/j.ajhg.2016.10.003 10.1164/rccm.201810-1891OC 10.1002/ijc.23907 10.1183/13993003.03545-2020 10.1136/jmedgenet-2014-102438 10.1056/NEJMoa1402582 10.1136/gutjnl-2012-303434 10.1126/sciadv.aba1983 10.1016/j.bjhh.2016.07.005 10.1038/nrcardio.2017.156 10.1056/NEJMoa1809944 10.1038/s41467-018-07768-9 10.7554/eLife.34408 10.1093/ije/dyx034 10.1002/gepi.21758 10.1093/hmg/ddx071 10.1093/bioinformatics/btq419 10.1016/S2213-2600(17)30430-7 10.1136/thoraxjnl-2018-212446 10.1183/13993003.00120-2015 10.1186/s12931-019-1190-z 10.1056/NEJMc1014719 10.1164/rccm.2009-040GL 10.1038/s41569-020-00493-1 10.1378/chest.96.1.68 10.1038/s41586-018-0175-2 10.1093/aje/kwy204 10.1371/journal.pgen.1007081 10.3390/ijms21072269 10.1038/s41467-018-05512-x 10.1016/S0140-6736(21)00676-0 10.1093/bioinformatics/btw018 10.1164/rccm.201509-1863OC 10.1093/ije/dyx038 10.1038/s41576-019-0127-1 10.1126/science.aaq1327 10.1126/sciadv.aba1972 10.1161/CIRCGENETICS.116.001396 10.1056/NEJMoa1013660 10.1371/journal.ppat.1005555 10.1093/bioinformatics/btw373 10.1371/journal.pgen.1004383 10.1378/chest.11-0284 10.1183/09031936.00077309 10.1016/S2213-2600(18)30185-1 10.1371/journal.pone.0092111 10.1136/thx.2010.151555 10.1016/S0140-6736(17)30866-8 10.1136/thoraxjnl-2012-202943 10.1164/rccm.201505-0862OC 10.1164/rccm.201905-1017OC 10.1002/sim.6835 10.1016/j.bbagen.2014.05.003 |
ContentType | Journal Article |
Copyright | Copyright ©The authors 2022. Copyright ©The authors 2022. 2022 |
Copyright_xml | – notice: Copyright ©The authors 2022. – notice: Copyright ©The authors 2022. 2022 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1183/13993003.03979-2020 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Genetically increased circulating FUT3 level and risk of IPF |
EISSN | 1399-3003 |
ExternalDocumentID | PMC8828995 34172473 10_1183_13993003_03979_2020 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R38 HL143511 – fundername: Department of Health – fundername: Wellcome Trust – fundername: Cancer Research UK – fundername: NHLBI NIH HHS grantid: UH3 HL123442 – fundername: NHLBI NIH HHS grantid: UH3 HL151865 – fundername: NHLBI NIH HHS grantid: UG3 HL151865 – fundername: NIEHS NIH HHS grantid: R25 ES025476 – fundername: NHLBI NIH HHS grantid: T32 HL007085 – fundername: NHLBI NIH HHS grantid: UH2 HL123442 – fundername: ; – fundername: ; grantid: 365825; 409511 |
GroupedDBID | --- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AADJU AAFWJ AAYXX AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG ADYFA AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CITATION COF CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 OK1 P2P PQQKQ R0Z RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 CGR CUY CVF ECM EIF NPM RHF 7X8 5PM |
ID | FETCH-LOGICAL-c405t-a8f2dfd7dab18ac274d8ef24274a04c0d65b7fd87662893d69203438846fa0aa3 |
ISSN | 0903-1936 1399-3003 |
IngestDate | Thu Aug 21 13:59:16 EDT 2025 Fri Jul 11 10:55:13 EDT 2025 Wed Feb 19 02:24:05 EST 2025 Thu Apr 24 22:50:55 EDT 2025 Tue Jul 01 05:42:46 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-a8f2dfd7dab18ac274d8ef24274a04c0d65b7fd87662893d69203438846fa0aa3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2660-7105 0000-0002-8450-3056 0000-0001-6743-8443 0000-0002-9633-7796 0000-0002-3108-6164 0000-0001-9510-5646 0000-0003-4963-0815 0000-0002-1018-489X 0000-0002-6061-4720 0000-0002-0348-0666 0000-0002-7929-2119 0000-0003-4951-1867 0000-0002-1503-5535 0000-0002-2497-9984 0000-0002-3746-9086 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8828995 |
PMID | 34172473 |
PQID | 2545597120 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8828995 proquest_miscellaneous_2545597120 pubmed_primary_34172473 crossref_citationtrail_10_1183_13993003_03979_2020 crossref_primary_10_1183_13993003_03979_2020 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-02-01 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The European respiratory journal |
PublicationTitleAlternate | Eur Respir J |
PublicationYear | 2022 |
Publisher | European Respiratory Society |
Publisher_xml | – name: European Respiratory Society |
References | 2024102102334771000_59.2.2003979.16 2024102102334771000_59.2.2003979.15 2024102102334771000_59.2.2003979.59 2024102102334771000_59.2.2003979.58 Allen (2024102102334771000_59.2.2003979.11) 2020; 201 2024102102334771000_59.2.2003979.13 Kamat (2024102102334771000_59.2.2003979.26) 2019; 35 Yao (2024102102334771000_59.2.2003979.32) 2018; 9 2024102102334771000_59.2.2003979.19 Fanidi (2024102102334771000_59.2.2003979.44) 2019; 145 2024102102334771000_59.2.2003979.18 2024102102334771000_59.2.2003979.17 2024102102334771000_59.2.2003979.52 2024102102334771000_59.2.2003979.51 2024102102334771000_59.2.2003979.50 2024102102334771000_59.2.2003979.12 2024102102334771000_59.2.2003979.56 2024102102334771000_59.2.2003979.55 2024102102334771000_59.2.2003979.10 2024102102334771000_59.2.2003979.54 2024102102334771000_59.2.2003979.53 Davey Smith (2024102102334771000_59.2.2003979.14) 2019; 7 2024102102334771000_59.2.2003979.27 2024102102334771000_59.2.2003979.25 2024102102334771000_59.2.2003979.24 2024102102334771000_59.2.2003979.29 2024102102334771000_59.2.2003979.28 Maher (2024102102334771000_59.2.2003979.57) 2017; 5 Nongmaithem (2024102102334771000_59.2.2003979.31) 2017; 26 2024102102334771000_59.2.2003979.60 2024102102334771000_59.2.2003979.23 2024102102334771000_59.2.2003979.22 2024102102334771000_59.2.2003979.21 2024102102334771000_59.2.2003979.38 2024102102334771000_59.2.2003979.37 Landray (2024102102334771000_59.2.2003979.42) 2021; 397 2024102102334771000_59.2.2003979.36 2024102102334771000_59.2.2003979.35 2024102102334771000_59.2.2003979.39 Neighbors (2024102102334771000_59.2.2003979.9) 2018; 6 Dupuy (2024102102334771000_59.2.2003979.49) 2002; 19 Giambartolomei (2024102102334771000_59.2.2003979.20) 2014; 10 Moore (2024102102334771000_59.2.2003979.47) 2019; 200 Raffield (2024102102334771000_59.2.2003979.61) 2020; 20 2024102102334771000_59.2.2003979.30 2024102102334771000_59.2.2003979.34 2024102102334771000_59.2.2003979.33 2024102102334771000_59.2.2003979.1 2024102102334771000_59.2.2003979.48 2024102102334771000_59.2.2003979.46 2024102102334771000_59.2.2003979.5 2024102102334771000_59.2.2003979.4 2024102102334771000_59.2.2003979.3 2024102102334771000_59.2.2003979.2 2024102102334771000_59.2.2003979.8 2024102102334771000_59.2.2003979.7 2024102102334771000_59.2.2003979.6 2024102102334771000_59.2.2003979.41 2024102102334771000_59.2.2003979.40 2024102102334771000_59.2.2003979.45 2024102102334771000_59.2.2003979.43 |
References_xml | – volume: 145 start-page: 1499 year: 2019 ident: 2024102102334771000_59.2.2003979.44 article-title: Is high vitamin B12 status a cause of lung cancer? publication-title: Int J Cancer doi: 10.1002/ijc.32033 – ident: 2024102102334771000_59.2.2003979.17 doi: 10.1136/bmj.k601 – volume: 35 start-page: 4851 year: 2019 ident: 2024102102334771000_59.2.2003979.26 article-title: PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations publication-title: Bioinformatics doi: 10.1093/bioinformatics/btz469 – volume: 19 start-page: 815 year: 2002 ident: 2024102102334771000_59.2.2003979.49 article-title: α1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently publication-title: Mol Biol Evol doi: 10.1093/oxfordjournals.molbev.a004138 – volume: 20 start-page: 1900278 year: 2020 ident: 2024102102334771000_59.2.2003979.61 article-title: Comparison of proteomic assessment methods in multiple cohort studies publication-title: Proteomics doi: 10.1002/pmic.201900278 – ident: 2024102102334771000_59.2.2003979.3 doi: 10.1056/NEJMoa1402584 – ident: 2024102102334771000_59.2.2003979.6 doi: 10.1371/journal.pmed.0050093 – ident: 2024102102334771000_59.2.2003979.21 doi: 10.1016/j.ajhg.2016.10.003 – volume: 200 start-page: 199 year: 2019 ident: 2024102102334771000_59.2.2003979.47 article-title: Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201810-1891OC – ident: 2024102102334771000_59.2.2003979.58 doi: 10.1002/ijc.23907 – ident: 2024102102334771000_59.2.2003979.43 doi: 10.1183/13993003.03545-2020 – ident: 2024102102334771000_59.2.2003979.45 doi: 10.1136/jmedgenet-2014-102438 – ident: 2024102102334771000_59.2.2003979.4 doi: 10.1056/NEJMoa1402582 – ident: 2024102102334771000_59.2.2003979.33 doi: 10.1136/gutjnl-2012-303434 – ident: 2024102102334771000_59.2.2003979.29 doi: 10.1126/sciadv.aba1983 – ident: 2024102102334771000_59.2.2003979.53 doi: 10.1016/j.bjhh.2016.07.005 – ident: 2024102102334771000_59.2.2003979.40 doi: 10.1038/nrcardio.2017.156 – ident: 2024102102334771000_59.2.2003979.39 doi: 10.1056/NEJMoa1809944 – ident: 2024102102334771000_59.2.2003979.56 doi: 10.1038/s41467-018-07768-9 – ident: 2024102102334771000_59.2.2003979.18 doi: 10.7554/eLife.34408 – ident: 2024102102334771000_59.2.2003979.23 doi: 10.1093/ije/dyx034 – ident: 2024102102334771000_59.2.2003979.19 doi: 10.1002/gepi.21758 – volume: 26 start-page: 2551 year: 2017 ident: 2024102102334771000_59.2.2003979.31 article-title: GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians publication-title: Hum Mol Genet doi: 10.1093/hmg/ddx071 – ident: 2024102102334771000_59.2.2003979.22 doi: 10.1093/bioinformatics/btq419 – volume: 5 start-page: 946 year: 2017 ident: 2024102102334771000_59.2.2003979.57 article-title: An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(17)30430-7 – ident: 2024102102334771000_59.2.2003979.5 doi: 10.1136/thoraxjnl-2018-212446 – ident: 2024102102334771000_59.2.2003979.52 doi: 10.1183/13993003.00120-2015 – ident: 2024102102334771000_59.2.2003979.35 doi: 10.1186/s12931-019-1190-z – ident: 2024102102334771000_59.2.2003979.50 doi: 10.1056/NEJMc1014719 – ident: 2024102102334771000_59.2.2003979.59 doi: 10.1164/rccm.2009-040GL – ident: 2024102102334771000_59.2.2003979.41 doi: 10.1038/s41569-020-00493-1 – ident: 2024102102334771000_59.2.2003979.8 doi: 10.1378/chest.96.1.68 – ident: 2024102102334771000_59.2.2003979.12 doi: 10.1038/s41586-018-0175-2 – ident: 2024102102334771000_59.2.2003979.10 doi: 10.1093/aje/kwy204 – ident: 2024102102334771000_59.2.2003979.34 doi: 10.1371/journal.pgen.1007081 – ident: 2024102102334771000_59.2.2003979.36 doi: 10.3390/ijms21072269 – volume: 9 start-page: 3268 year: 2018 ident: 2024102102334771000_59.2.2003979.32 article-title: Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease publication-title: Nat Commun doi: 10.1038/s41467-018-05512-x – volume: 397 start-page: 1637 year: 2021 ident: 2024102102334771000_59.2.2003979.42 article-title: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00676-0 – ident: 2024102102334771000_59.2.2003979.30 doi: 10.1093/bioinformatics/btw018 – ident: 2024102102334771000_59.2.2003979.46 doi: 10.1164/rccm.201509-1863OC – ident: 2024102102334771000_59.2.2003979.16 doi: 10.1093/ije/dyx038 – ident: 2024102102334771000_59.2.2003979.15 doi: 10.1038/s41576-019-0127-1 – ident: 2024102102334771000_59.2.2003979.13 doi: 10.1126/science.aaq1327 – ident: 2024102102334771000_59.2.2003979.28 doi: 10.1126/sciadv.aba1972 – ident: 2024102102334771000_59.2.2003979.38 doi: 10.1161/CIRCGENETICS.116.001396 – ident: 2024102102334771000_59.2.2003979.55 doi: 10.1056/NEJMoa1013660 – ident: 2024102102334771000_59.2.2003979.54 doi: 10.1371/journal.ppat.1005555 – ident: 2024102102334771000_59.2.2003979.25 doi: 10.1093/bioinformatics/btw373 – volume: 10 start-page: e100438 year: 2014 ident: 2024102102334771000_59.2.2003979.20 article-title: Bayesian test for colocalisation between pairs of genetic association studies using summary statistics publication-title: PLoS Genet doi: 10.1371/journal.pgen.1004383 – ident: 2024102102334771000_59.2.2003979.60 doi: 10.1378/chest.11-0284 – ident: 2024102102334771000_59.2.2003979.2 doi: 10.1183/09031936.00077309 – volume: 6 start-page: 615 year: 2018 ident: 2024102102334771000_59.2.2003979.9 article-title: Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30185-1 – ident: 2024102102334771000_59.2.2003979.48 doi: 10.1371/journal.pone.0092111 – ident: 2024102102334771000_59.2.2003979.37 doi: 10.1136/thx.2010.151555 – ident: 2024102102334771000_59.2.2003979.1 doi: 10.1016/S0140-6736(17)30866-8 – ident: 2024102102334771000_59.2.2003979.27 doi: 10.1136/thoraxjnl-2012-202943 – ident: 2024102102334771000_59.2.2003979.7 doi: 10.1164/rccm.201505-0862OC – volume: 7 start-page: 27857v year: 2019 ident: 2024102102334771000_59.2.2003979.14 article-title: STROBE-MR: guidelines for strengthening the reporting of Mendelian randomisation studies publication-title: Peer J Preprints – volume: 201 start-page: 564 year: 2020 ident: 2024102102334771000_59.2.2003979.11 article-title: Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201905-1017OC – ident: 2024102102334771000_59.2.2003979.24 doi: 10.1002/sim.6835 – ident: 2024102102334771000_59.2.2003979.51 doi: 10.1016/j.bbagen.2014.05.003 |
SSID | ssj0016431 |
Score | 2.4466915 |
Snippet | Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal... After undertaking an efficient scan of 834 circulating proteins for their role in IPF risk using Mendelian randomisation, we found that individuals with... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2003979 |
SubjectTerms | Fucosyltransferases - genetics Genome-Wide Association Study Humans Idiopathic Pulmonary Fibrosis - genetics Mendelian Randomization Analysis - methods Original s Polymorphism, Single Nucleotide |
Title | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34172473 https://www.proquest.com/docview/2545597120 https://pubmed.ncbi.nlm.nih.gov/PMC8828995 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKkKZdEN-ULxmJW8nIh9M43CZENYGGhNSiiUvk2s4W1iZVmlx25s6_zHtO4qTbQMAlqpLYSfr7JX7v-fn3CHkdhO5SCaGdFMY7h8kY3jnf5Y4KQrmMdSA9Izx_8nl6vGAfT8PT0ejnIGuprpaH8vLGdSX_gyrsA1xxlew_IGs7hR3wG_CFLSAM27_CGDWjTSx6hav30P7bgv0os1Kaolz52WS2mAeTFSYGYX0IZeQcSlRr1X1WeaaywhQmlpNNvYKbx0S6FNzoYpttm8XQJxgoNwERGNpUsW5zgAbitN971tkAfzmYxh8-D8aexYXIMfxl-FKsi4vCzobosqkzNTk6w1Jjlr0zE71vrN2v8Lg6v7SNvp0XtQnkZmWdDSMZ4AS7NitEN19fsJacwHWD4ee5FQzPei_5-lefo_oEtsbGhy7OVQJRzCq7asCDzdoQAQbuyGdNBZUrYtvdoVvktg9-B5bE-PSln5YC881rpavgmm9vuOIB2e_62LV0rrkvV7NwB2bN_C650_oj9Kgh1z0y0vl9sn_SZlw8ID8GHKOWY3TAMYoco4Zj1HCMVgVtOUaRY7RIac8xajlGO469o4JahtEdhlHDsIdkMfswf3_stJU7HAkOQOUInvoqVZESS48L6UdMcZ2CNRgx4TLpqmm4jFIFI_EUHP5ATWPfDVjAwRhOhStE8Ijs5UWunxAaCpFqJUIRM87SSMUpn3pce4zxWEimx8Tv_uVEtrL2WF1llRj3lgdJh1JiUEoQpTF5YxttGlWXP5_-qoMvgefHKTWR66LeJj44IOCSe3jO4wZO22HHgzGJdoC2J6Cy--6RPDs3Cu_cxEHCp7_t8xk56N-g52SvKmv9AqzjavnSMPYXSUW-VA |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetically+increased+circulating+FUT3+level+leads+to+reduced+risk+of+idiopathic+pulmonary+fibrosis%3A+a+Mendelian+randomisation+study&rft.jtitle=The+European+respiratory+journal&rft.au=Nakanishi%2C+Tomoko&rft.au=Cerani%2C+Agustin&rft.au=Forgetta%2C+Vincenzo&rft.au=Zhou%2C+Sirui&rft.date=2022-02-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=2&rft_id=info:doi/10.1183%2F13993003.03979-2020&rft_id=info%3Apmid%2F34172473&rft.externalDocID=34172473 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon |